JP2021502416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502416A5 JP2021502416A5 JP2020544565A JP2020544565A JP2021502416A5 JP 2021502416 A5 JP2021502416 A5 JP 2021502416A5 JP 2020544565 A JP2020544565 A JP 2020544565A JP 2020544565 A JP2020544565 A JP 2020544565A JP 2021502416 A5 JP2021502416 A5 JP 2021502416A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- patient
- cells
- cancer
- chain sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023181486A JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
| JP2025115696A JP2025148435A (ja) | 2017-11-03 | 2025-07-09 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581380P | 2017-11-03 | 2017-11-03 | |
| US62/581,380 | 2017-11-03 | ||
| US201762592778P | 2017-11-30 | 2017-11-30 | |
| US62/592,778 | 2017-11-30 | ||
| PCT/US2018/059039 WO2019090134A1 (en) | 2017-11-03 | 2018-11-02 | Monoclonal antibody neo-201 for the treatment of human carcinomas |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181486A Division JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502416A JP2021502416A (ja) | 2021-01-28 |
| JP2021502416A5 true JP2021502416A5 (cg-RX-API-DMAC7.html) | 2021-12-02 |
| JP7437307B2 JP7437307B2 (ja) | 2024-02-22 |
Family
ID=66332711
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544565A Active JP7437307B2 (ja) | 2017-11-03 | 2018-11-02 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
| JP2023181486A Active JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
| JP2025115696A Pending JP2025148435A (ja) | 2017-11-03 | 2025-07-09 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181486A Active JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
| JP2025115696A Pending JP2025148435A (ja) | 2017-11-03 | 2025-07-09 | ヒトがんの治療のためのモノクローナル抗体neo-201 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11767367B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3735423A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7437307B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN120860200A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018360045B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019090134A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7555270B2 (ja) * | 2018-02-13 | 2024-09-24 | プレシジョン バイオロジックス、インコーポレイテッド | Treg細胞を標的とするための方法及び組成物 |
| MX2023013637A (es) * | 2021-05-19 | 2024-02-13 | Prec Biologics Inc | Metodos y composiciones para tratar neoplasias hematicas. |
| CN115678854A (zh) * | 2021-07-29 | 2023-02-03 | 上海中医药大学 | 一种基因工程细胞及其制备方法和应用 |
| CN115819596B (zh) * | 2021-09-17 | 2026-06-02 | 优迈生物科技(连云港)有限公司 | 一种靶向人ceacam5/6的抗体、制备方法和应用 |
| WO2023198019A1 (zh) * | 2022-04-12 | 2023-10-19 | 盛禾(中国)生物制药有限公司 | 一种抗ceacam5和ceacam6抗体及其应用 |
| CN116699135B (zh) * | 2022-04-29 | 2025-11-07 | 中国医学科学院肿瘤医院 | 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用 |
| EP4499710A4 (en) * | 2022-05-19 | 2026-04-15 | Prec Biologics Inc | METHODS FOR ABLATION OF SUPPRESSIVE MYELOID CELLS USING A NEO-201 ANTIBODY |
| TW202617186A (zh) | 2024-06-28 | 2026-05-01 | 美商飛爾富來生物公司 | Bcl-xl降解劑抗體結合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2803391C (en) | 2010-06-22 | 2021-11-09 | Neogenix Oncology, Inc. | Npc1 antibodies that bind a muc5ac epitope |
| EP3336104A1 (en) * | 2012-12-28 | 2018-06-20 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| CA2953816C (en) * | 2014-06-30 | 2022-03-15 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| US11020467B2 (en) * | 2017-05-26 | 2021-06-01 | Etubics Corporation | Combination immunotherapies comprising IL-15 superagonists |
-
2018
- 2018-11-02 CN CN202510631395.3A patent/CN120860200A/zh active Pending
- 2018-11-02 US US16/761,404 patent/US11767367B2/en active Active
- 2018-11-02 CN CN202411004231.XA patent/CN119587690A/zh active Pending
- 2018-11-02 WO PCT/US2018/059039 patent/WO2019090134A1/en not_active Ceased
- 2018-11-02 JP JP2020544565A patent/JP7437307B2/ja active Active
- 2018-11-02 CN CN201880085205.0A patent/CN111670199B/zh active Active
- 2018-11-02 AU AU2018360045A patent/AU2018360045B2/en active Active
- 2018-11-02 EP EP18907474.3A patent/EP3735423A4/en active Pending
-
2023
- 2023-09-22 US US18/472,411 patent/US20240101702A1/en active Pending
- 2023-10-20 JP JP2023181486A patent/JP7712338B2/ja active Active
-
2025
- 2025-07-09 JP JP2025115696A patent/JP2025148435A/ja active Pending
- 2025-07-14 AU AU2025205420A patent/AU2025205420A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Breakthrough of solid tumor treatment: CAR-NK immunotherapy | |
| Sun et al. | CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies | |
| Darragh et al. | Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| Joshi et al. | Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system | |
| Seyedin et al. | Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models | |
| Herrera et al. | Radiotherapy combination opportunities leveraging immunity for the next oncology practice | |
| Fournier et al. | Trial watch: adoptively transferred cells for anticancer immunotherapy | |
| Bhalla et al. | Combining immunotherapy and radiotherapy in lung cancer | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| RU2689160C2 (ru) | Противораковая таргетная иммунотерапия с применением il-12 | |
| JP2017536812A (ja) | バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞 | |
| KR20200029543A (ko) | 암 면역요법을 위해 면역 조절제와 조합된 수용체 서브타입 및 기능 선택적 레티노이드 및 렉시노이드 화합물 | |
| He et al. | Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors | |
| US20220111069A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
| CA3128202A1 (en) | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment | |
| JP2018516881A (ja) | 癌治療のためのnk細胞および抗体 | |
| Doloff et al. | Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2 | |
| Wang et al. | Combination of cytokine-induced killer cells and programmed cell death-1 blockade works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and non-small cell lung cancer | |
| Wieder et al. | Immunotherapy of melanoma: efficacy and mode of action | |
| Guo et al. | Tumor reductive therapies and antitumor immunity | |
| JP2024514149A (ja) | uPARを標的とするCAR-T細胞及びその使用 | |
| JP2020500161A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Prospects and applications of NK therapy in the treatment of gliomas | |
| Chen et al. | Immunotherapy of Cancer by Targeting Regulatory T cells |